位元堂(00897.HK)年度總收益增加約8.3%至約7.84億港元
格隆匯6月26日丨位元堂(00897.HK)公吿,截至2024年3月31日止財政年度,集團總收益增加約8.3%至約7.84億港元,乃主要由於藥品及保健食品產品銷售增加所致。集團錄得母公司擁有人應占虧損約1540萬港元(2023年:母公司擁有人應占虧損約2050萬港元)。每股基本及攤薄虧損1.30港仙。
有關虧損減少乃主要由於以下各項的綜合影響(i)生產及銷售藥品及保健食品產生的毛利增加;(ii)出售物業、廠房及設備項目收益;(iii)自有投資物業公平值虧損增加;(iv)出售╱贖回債務投資虧損增加;及(v)物業、廠房及設備項目減值虧損增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.